Drugs / Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00772629 | Jan → Apr 2004 | meningitis, meningococcemia | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded |
| Phase 2 | NCT00771849 | Aug 2003 → Mar 2004 | meningitis, meningococcemia | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01519713 | Jan → Sep 2012 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00269477 Comparator | Dec 2005 → Feb 2007 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal Polysaccharide Diphtheria Toxoid Conjugate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00771849 ↗ |
| Modality | Vaccine | “Menactra® vaccine” NCT00269477 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT00269477 ↗ |